Results 41 to 50 of about 9,194 (267)
Development of a method for control of radiopharmaceuticals [PDF]
, 2021 The aim of the study is to draw up a method for monitoring the isotopic composition of medical solutions of radium-223. The possibility of using gamma spectrometry for control of radium-223, its decay products, and its parent isotopes are considered in ...
Безденежных, Илья Викторович +13 more
core +2 more sources
BMC Cancer, 2020 Background Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. Additionally, within a prostate-cancer-
Hamza Hasan +30 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2021 Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of ...
Raymond S. McDermott +13 more
doaj +1 more source
World Journal of Nuclear Medicine, 2021 A retrospective analysis was performed of epidemiological data assessing the survival of patients who had received radium-223 for castrate-resistant metastatic prostate cancer treated at a regional tertiary referral center over a 5-year period.
John Buscombe +5 more
doaj +1 more source
Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer [PDF]
, 2016 The baseline value of neutrophil to lymphocyte ratio (NLR) has been found to be prognostic in patients with metastatic castration resistant prostate cancer (CRPC). We evaluated the impact of baseline NLR and its change in patients receiving enzalutamide.
Caffo, Orazio +15 more
core +3 more sources
Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points [PDF]
European Medical Journal Urology, 2015 The Bayer satellite symposium was introduced by Prof Fred Saad, who gave an introduction into the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).
Fred Saad +3 more
doaj
World Journal of Nuclear Medicine, 2022 Aim Radium-223 has been the first-approved targeted Alpha therapy agent. We retrospectively assessed different factors influencing the overall survival (OS) and patient management.
Amit Bhoil +3 more
doaj +1 more source
Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment [PDF]
, 2020 BACKGROUND: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop combination therapies have not translated into new treatments. We sought to develop a novel therapeutic strategy to tackle chemoresistant
Dufès, Christine +9 more
core +3 more sources
Journal of Health Economics and Outcomes Research, 2018 # Purpose To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain.
Eva Tirado Mercier +4 more
doaj +1 more source
First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. [PDF]
, 2018 PURPOSE: To investigate the utility of 153Sm lexidronam (Quadramet) in the setting of men with prostate cancer status post radical prostatectomy who develop biochemical failure with no clinical evidence of osseous metastases.
Girvigian, Michael R. +10 more
core +2 more sources